Compare AU
Compare RGOS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are RGOS and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
RGOS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 80 |
Median incremental investment | $0 | $620.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,325.53 |
Average age group | N/A | > 35 |
Key Summary
RGOS | CURE | |
|---|---|---|
Strategy | RGOS.AX was created on 2024-04-12 by Russell. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the Funds benchmark, before costs and tax, over the long term by providing exposure to a diversified portfolio of predominantly international shares. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Russell Sust Global Opportunities Complex ETF (100 %) | Neurocrine Biosciences Inc (2.68 %) Alnylam Pharmaceuticals Inc (2.53 %) Insmed Inc (2.44 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0 % | 0.45 % |
Key Summary
RGOS | CURE | |
|---|---|---|
Issuer | Russell | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $22.22 | $50.44 |
Size | N/A | $34.226 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 0.87 % | 4.24 % |
Market | ASX | ASX |
First listed date | 15/04/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RGOS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 80 |
Median incremental investment | $0 | $620.50 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,325.53 |
Average age group | N/A | > 35 |
Pros and Cons
RGOS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RGOS | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |